Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction
Michael E. Nassif(Saint Luke's Health System), John M. Cox, Kenneth B. Margulies(Temple University), Silvio E. Inzucchi(Yale University), Brenda Murphy, Sheryl L. Windsor(Saint Luke's Hospital), Maria Rosa Costanzo(National Heart Foundation of Australia), Sumant Lamba(First Coast Cardiovascular Institute), Bethany A. Austin(Saint Luke's Hospital), David E. Lanfear(Henry Ford Health System), Alicia Warnock, JoAnn Lindenfeld(Brigham and Women's Hospital), R. Kannan Mutharasan(Northwestern University), W.H. Wilson Tang(Cleveland Clinic), Rita Jermyn(St. Francis Hospital), Shane LaRue(Washington University in St. Louis), Bertram Pitt(Bayer (Germany)), Mansoor Husain(Tawam Hospital), Michael Pursley(The Heart House), Benjamin M. Scirica(Brigham and Women's Hospital), Ali O. Malik(Saint Luke's Hospital), Jonathan Newman(New York University), Mikhail Kosiborod(AstraZeneca (Brazil)), Nannette Wenger, Priyathama Vellanki(Emory University), Guillermo E. Umpierrez(Emory University), Stuart D. Katz(Andover Eye Associates), Yevgeniy Khariton(Saint Luke's Hospital), Robert J. Mentz(Duke University), Stephen S. Gottlieb(University of Maryland, Baltimore), Paramdeep Baweja, Darren K. McGuire(Parkland Health & Hospital System), Modele O. Ogunniyi, Mark H. Drazner(Southwestern Medical Center), Thanh T. Hoang, Larry A. Allen(University of Colorado Denver), Michael M. Givertz(Brigham and Women's Hospital), Horng H. Chen, Charu Gupta, Michael Malone(Imaging the World), Justin Hartupee(Washington University in St. Louis), Fengming Tang(Saint Luke's Hospital), Manuel Montero, Michael Fong(University of Southern California), Marcela Goldsmith, Robert Gordon(The University of Texas Health Science Center at Houston)
Cited by 427
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k